Shares of VolitionRX Limited (NYSEAMERICAN:VNRX – Get Free Report) have been assigned a consensus recommendation of “Hold” from the six analysts that are covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $28.00.
A number of equities analysts have issued reports on the stock. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research note on Monday, August 17th. Freedom Broker cut shares of VolitionRX from a “buy” rating to a “hold” rating in a research report on Wednesday.
Get Our Latest Research Report on VNRX
VolitionRX Price Performance
Shares of NYSEAMERICAN:VNRX opened at $0.19 on Wednesday. VolitionRX has a one year low of $0.16 and a one year high of $7.73. The company has a 50 day moving average of $0.22 and a 200-day moving average of $1.87. The stock has a market cap of $2.58 million, a price-to-earnings ratio of -0.06 and a beta of 1.16.
VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The medical research company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.18. The business had revenue of $1.61 million for the quarter, compared to the consensus estimate of $0.71 million. Equities research analysts anticipate that VolitionRX will post -1.55 earnings per share for the current year.
VolitionRX Company Profile
VolitionRx Ltd. is a diagnostics company developing blood-based tests for cancer and other diseases. Its Nu.Q technology measures nucleosomes—DNA-protein structures released into the bloodstream—as potential biomarkers for detecting and monitoring disease. The company is developing Nu.Q tests for human health applications and has also pursued veterinary diagnostics, including Nu.Q Vet tests intended to help identify cancer in dogs. Its products and programs are at varying stages of development and commercialization.
Featured Stories
- Five stocks we like better than VolitionRX
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.
